The mean duration of motor unit action potentials in patients with myasthenia gravis.
D000200:Action Potentials; D000251:Adenosine Triphosphatases / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D006801:Humans; D009046:Motor Neurons; D009119:Muscle Contraction; D009132:Muscles / Q000201:enzymology / Q000503:physiopathology*; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology*; D009388:Neostigmine / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use
D009388:Neostigmine; D000251:Adenosine Triphosphatases; D011729:Pyridostigmine Bromide; D002118:Calcium